Form 4: Ocular Therapeutix Director Lindstrom Reports Stock Option Exercises and RSU Grant

Director Richard L. Lindstrom reports exercising stock options and receiving restricted stock units in Ocular Therapeutix, Inc.

Summary

• Richard L. Lindstrom, a director of Ocular Therapeutix, Inc., reported changes in beneficial ownership of the company's stock.
• On February 27, 2024, Lindstrom exercised options to purchase 18,939 and 11,363 shares of common stock at a price of $8.8 per share.
• On July 24, 2024, Lindstrom was granted 12,000 restricted stock units (RSUs) under the company's 2021 Stock Incentive Plan.
• These RSUs will vest on the first anniversary of the grant date or immediately prior to the next annual meeting of stockholders, contingent upon continued service on the board.
• Additionally, Lindstrom was granted options to purchase 36,000 shares of common stock at an exercise price of $7.91 on July 24, 2024, which also vest on the first anniversary of the grant date or immediately prior to the next annual meeting of stockholders, contingent upon continued service on the board.
• Following these transactions, Lindstrom directly owns 162,704 shares of Ocular Therapeutix common stock and options to purchase 36,000 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports transactions related to executive compensation, which is a routine occurrence. The director's continued investment is a mildly positive signal.

Positives

• The director's continued investment in the company through option exercises and RSU grants could be seen as a positive signal.

Future Outlook

The RSUs and stock options granted on July 24, 2024, will vest on the first anniversary of the grant date or immediately prior to the next annual meeting of stockholders, contingent upon continued service on the board.

Industry Context

Stock option exercises and RSU grants are common forms of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages in biotech often include a mix of salary, stock options, and restricted stock units.
• Companies like Regeneron and Vertex Pharmaceuticals also utilize similar equity-based compensation plans for their directors and executives.
• The vesting schedules and exercise prices are generally in line with industry norms for companies of similar size and stage of development.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly diluting the stock.

Key Dates